Medrio Inc. a provider of decentralized and eClinical technology to pharmaceutical, medical device, biotech, diagnostics, and animal health markets, and Phastar, a global specialist biometrics clinical research organization (CRO) offering data management, data science, statistical consulting, and clinical trial reporting services, have partnered to leverage metadata surrounding electronic patient-reported outcomes (ePRO) for advanced data visualization, providing insight into patient compliance and burden.
 
Phastar ran a pilot with 33 volunteers completing EQ-5D, a health-related measure of quality-of-life questionnaire, to understand how metadata may be used effectively to monitor ePRO data collection during a study.
 
“Whilst sites may monitor compliance at the individual subject level, data management teams can take a broader view. We looked at how the metadata surrounding the ePRO data can be used to monitor compliance, patient burden, and any anomalies that may ultimately impact the
interpretation of the results,” explained Jennifer Bradford, director of data science at Phastar.
 
The Phastar team used Medrio ePRO for initial data collection and Medrio’s Export API to funnel the ePRO and metadata into Phastar’s data visualization tool, Phizual.
 
“Data visualization provides data management teams the ability to monitor compliance and see any anomalies in real-time, ultimately providing the highest quality data reflective of the patient population as a whole rather than at the subject level,” detailed Bradford. “This wouldn’t have been possible without Medrio’s ePRO and Export API. These tools offered us an intuitive customer and patient-friendly experience while seamlessly integrating the data we needed. We would not have been successful without the flexibility and agility that Medrio provided along with their worldclass support team.”
 
“Medrio is thrilled to support and enable data visualization with Phastar. At Medrio we continuously look to be innovative and stay ahead of the curve to provide efficiencies and accurate data that serve not only our sponsors and CROs but the patients as well. Getting a holistic view of patient data is a necessary piece to the democratization of clinical trials. We look forward to continuing to work with Phastar on improving data quality and accuracy,” added Fred Martin, chief product officer of Medrio.